iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Emcure Pharmaceuticals Refiles IPO Papers with SEBI

18 Dec 2023 , 12:59 PM

Pune-based Emcure Pharmaceuticals has refiled its preliminary papers with the capital markets regulator SEBI for fundraising via an initial public offering (IPO). The IPO comprises a mix of fresh shares amounting to Rs 800 crore and an offer-for-sale (OFS) of 1.37 crore equity shares by existing shareholders, both of which are smaller in size compared to the company’s previous fundraising plan.

Promoters and promoter group members, including Satish Ramanlal Mehta and Sunil Rajanikant Mehta, are set to sell 49.85 lakh equity shares in the OFS, while investor BC Investments IV will offload 72.34 lakh equity shares, according to draft papers filed on December 16. Other stakeholders, such as Arunkumar Purshotamlal Khanna, Berjis Minoo Desai, and Sonali Sanjay Mehta, will also participate in the OFS.

Emcure Pharma had initially filed draft papers for its IPO in August 2021, outlining a fresh issue of Rs 1,100 crore and an OFS of 1.8 crore equity shares. The fundraising target was estimated to be in the range of Rs 4,500-5,000 crore, as per sources. Although the company received approval from SEBI to proceed with the IPO plans in December 2021, it did not launch the IPO at that time.

Subdued market conditions, coupled with underperformance in the pharma sector from October 2021 to March 2023, may have contributed to the delay. The company now aims to utilize the net fresh issue proceeds primarily for repaying debts totaling Rs 640 crore and for general corporate purposes. As of September 2023, Emcure’s total borrowings stood at Rs 2,012.9 crore.

Emcure, the 13th largest pharmaceutical company in India, operates globally, with a strong presence in India, Europe, and Canada. It is the fourth largest pharmaceutical company by market share in covered markets and holds the top position in gynecology and HIV antivirals therapeutic areas in India.

Emcure’s financial performance saw improvement in the current financial year after a weak performance in the last fiscal year. For the year ended March FY23, net profit declined by 20% to Rs 561.8 crore, with revenue from operations increasing by 2.2% to Rs 5,986 crore. However, for the six months ending September FY24, net profit surged by 31.3% to Rs 286.8 crore, and revenue rose by 15.3% to Rs 3,219.3 crore compared to the same period in the previous financial year.

Kotak Mahindra Capital Company, Axis Capital, Jefferies India, and JP Morgan India have been appointed as merchant bankers for the IPO.

Emcure Pharma

Related Tags

  • Emcure Pharmaceuticals
  • Emcure Pharmaceuticals DRHP
  • Emcure Pharmaceuticals IPO
  • Emcure Pharmaceuticals IPO details
  • Emcure Pharmaceuticals OFS
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.